Status:
COMPLETED
An Observational Study to Learn More About the Impact of Gadoxetate Sodium-Enhanced Magnetic Resonance Imaging (EOB-MRI) When Used to Diagnose the Spread of Cancer From the Pancreas to the Liver in Japanese People Under Real-World Conditions
Lead Sponsor:
Bayer
Conditions:
Metastatic Pancreatic Cancer
Liver Metastases
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational study in which data from people with cancer that has spread from the pancreas to the liver are collected and studied. These adults will include people who already received the...
Eligibility Criteria
Inclusion
- Patients having at least one confirmed diagnosis of pancreatic cancer (identified by ICD-10 diagnosis code C25.x, without a suspicious diagnosis flag) during the patient selection period
- Patients having at least one active treatment record after the 1st confirmed diagnosis of pancreatic cancer
- Patients 18 years of age or older at the index date
- Patients having any recorded CE-CT or EOB-MRI or MRI without EOB record during the baseline period
- EOB-MRI stands for enhanced liver MRI using gadoxetate sodium as the contrast agent. In this type of MRI, gadoxetate sodium is used as a contrast agent in the visualization of the liver tumor.
- EOB-MRI group will include patients who underwent EOB-MRI during the baseline period.
- Non-EOB-MRI group will include patients who underwent CE-CT or MRI with contrast agent other than the gadoxetate sodium during the baseline period.
- MRI, CE-CT and contrast agents are identified by using the nine-digit Japanese receipt code specified in the separate code list
Exclusion
- Patients with no confirmed diagnosis of pancreatic cancer (ICD-10 diagnosis code C25.x) in the below category of the disease name in the discharge summary until the 1st discharge date after the index date:
- "ICD-10 code of disease name which input the most medical resources"
- "ICD-10 name of disease behind hospitalization"
- Patients with no active treatment within 3 months (90 days) from the con-firmed pancreatic cancer diagnosis date
- Patients with no medical record in the MDV database within 1 month (30 days) from the index date
Key Trial Info
Start Date :
November 20 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 30 2024
Estimated Enrollment :
39624 Patients enrolled
Trial Details
Trial ID
NCT06106568
Start Date
November 20 2023
End Date
October 30 2024
Last Update
November 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many locations
Multiple Locations, Japan